TRANSDUR-Sufentanil, DURECT’s proprietary investigational transdermal patch, may be able to treat moderate-to-severe chronic pain for a period of 7 days after a single application.
Opioid drugs expose users to risks of addiction, abuse and misuse. TRANSDUR-Sufentanil is an investigational product and has not been approved by the FDA for marketing in the U.S. for any indication.
TRANSDUR®-Sufentanil may have the ability to:
- Provide a longer duration of analgesia (7 days) than fentanyl patches (2-3 days) or OxyContin (1 day)
- Allow a smaller size than fentanyl-based patches, which could result in less skin irritation
- Exhibit an improved side-effect profile compared with other opioid therapies
TRANSDUR®-Sufentanil is an investigational product and has not been approved by the FDA for marketing in the U.S. for any indication.
Chronic pain affects as many as 100 million Americans annually. When chronic pain is severe, patients may be prescribed long-acting opioid analgesics. Fentanyl patches, including the Duragesic® brand, accounted for approximately $1.7 billion in worldwide sales in 2014.
Opioid medications expose users to the risks of addiction, abuse, and misuse. ORADUR-Sufentanil is an investigational product and has not been approved by the FDA for marketing in the U.S. for any indication.
Eight Phase 1 trials and a positive Phase 2 trial of TRANSDUR-Sufentanil have been completed. Further development is contingent upon the signing of a development and commercialization partner.
DURECT holds the worldwide rights to develop and commercialize TRANSDUR-Sufentanil.
There are risks and uncertainties associated with our business. Please see our most recent SEC filings (10-K or 10-Q) for a complete description of these risks and uncertainties, which are incorporated herein by reference.